# JAN 4 2006

# 510(k) Summary

# FastPack® TSH Immunoassay on the FastPack® System

This summary of 510(k) safety and effectiveness is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

1. Submitter name, address, contact

Qualigen, Incorporated 2042 Corte del Nogal Carlsbad, CA 92011

Telephone: (760) 918-9165   
Fax: (760) 918-9127

Contact Person: Dorothy Peterson

Date Prepared: August 15, 2005

Device name

Proprietary name: FastPack ® TSH Immunoassay on the FastPack® System

Common name: Chemiluminescence assay for the determination of TSH

Classification Name: Quantitative Determination of TSH in Human Plasma

# 3 Predicate device

4 Device description

# FastPack® TSH Immunoassay Reagents

The FastPack® TSH Immunoassay is a competitive chemiluminescence assay.

Primary incubation: Sample, calibrator, or control (100 μL) is added to the antibody solution (100 pL) to start the sequence. The reaction time is 10 minutes at $3 7 ^ { \circ } \mathrm { C }$ .   
Secondary incubation: The initial reaction mixture (200 μL) is transferred to the magnetic particles and is incubated an additional 2 minutes at $3 7 ^ { \circ } \mathrm { C }$ .   
Removal of unbound materials: The paramagnetic particles are washed three times with wash buffer (0.2 mL/wash cycle) to remove unbound materials.   
Substrate addition and detection: Chemiluminogenic substrate [140 $\mu \mathrm { L } \big ]$ is added to the solid phase bound complex to form a   
chemiluminescent glow, which is measured by the FastPack® System at $3 7 ^ { \circ } \mathrm { C }$ .

# 5. Intended use

The FastPack® TSH Immunoassay is a paramagnetic particle immunoassay intended for the in vitro quantitative determination of TSH in human plasma. The measurements of thyroid stimulating hormone (TSH) produced by the anterior pituitary are used in the diagnosis of thyroid or pituitary disorders. The FastPack® TSH Immunoassay is designed for use with the FastPack® System.

The following tables compare the FastPack® Immunoassay System for TSH with the Abbott Laboratories Ultrasensitive TSH II method.

6. Comparison to Predicate Device   

<table><tr><td rowspan=1 colspan=2>Feature</td><td rowspan=1 colspan=2>FastPack System</td><td rowspan=1 colspan=1>Abbott IMx® System</td></tr><tr><td rowspan=1 colspan=2>Intended Use</td><td rowspan=1 colspan=2>For the quantitativemeasurement of Thyroid-Stimulating Hormone(TSH) in human plasma.The measurements ofthyroid stimulatinghormone (TSH) producedby the anterior pituitaryare used in the diagnosis ofthyroid or pituitarydisorders.</td><td rowspan=1 colspan=1>For the quantitativemeasurement of Thyroid-Stimulating Hormone (TSH)in human serum andheparinized plasma.</td></tr><tr><td rowspan=1 colspan=2>AssayMethodology:</td><td rowspan=1 colspan=2>Sandwich immunoassay</td><td rowspan=1 colspan=1>Sanwich immunoassay</td></tr><tr><td rowspan=1 colspan=2>StorageCondition:</td><td rowspan=1 colspan=2>2-8 °C</td><td rowspan=1 colspan=1>2-8 °C</td></tr><tr><td rowspan=1 colspan=1>Data Analysis</td><td></td><td rowspan=1 colspan=2>Internal data reduction viamicrocomputer</td><td rowspan=1 colspan=1>Internal data reduction viamicrocomputer</td></tr><tr><td rowspan=1 colspan=2>TemperatureControl</td><td rowspan=1 colspan=2>Required</td><td rowspan=1 colspan=1>Required</td></tr><tr><td rowspan=1 colspan=1>Test Processing</td><td rowspan=1 colspan=2>Automated</td><td></td><td rowspan=1 colspan=1>Automated</td></tr><tr><td rowspan=1 colspan=1>Sample Type:</td><td rowspan=1 colspan=2>Plasma</td><td></td><td rowspan=1 colspan=1>Serum, Heparinized Plasma</td></tr><tr><td rowspan=1 colspan=1>Detector:</td><td rowspan=1 colspan=2>Photomultiplier Tube(PMT)</td><td rowspan=1 colspan=2>Photomultiplier Tube (PMT)</td></tr><tr><td rowspan=1 colspan=1>Label</td><td rowspan=1 colspan=2>Alkaline Phosphatase</td><td rowspan=1 colspan=2>Alkaline Phosphatase</td></tr><tr><td rowspan=1 colspan=1>Sample Volume</td><td rowspan=1 colspan=2>100 μL</td><td rowspan=1 colspan=2>150 μL</td></tr><tr><td rowspan=1 colspan=1>Assay Range</td><td rowspan=1 colspan=2>0 to 100 μIU/mL</td><td rowspan=1 colspan=2>0 to 100 μlU/mL</td></tr><tr><td rowspan=1 colspan=1>InstrumentRequired</td><td rowspan=1 colspan=2>FastPack System</td><td rowspan=1 colspan=2>Abbott IMx System</td></tr><tr><td rowspan=1 colspan=1>Control Levels</td><td rowspan=1 colspan=2>2</td><td rowspan=1 colspan=2>3</td></tr><tr><td rowspan=1 colspan=1>Antibody</td><td rowspan=1 colspan=2>Monoclonal/Monoclonal</td><td rowspan=1 colspan=2>Monoclonal/Polyclonal</td></tr><tr><td rowspan=1 colspan=1>Solid Phase</td><td rowspan=1 colspan=2>Paramagnetic particles</td><td rowspan=1 colspan=2>Latex Microparticles</td></tr><tr><td rowspan=1 colspan=1>Substrate</td><td rowspan=1 colspan=2>ImmuGlowTM (Indoxyl -3-phosphate and lucigenin)</td><td rowspan=1 colspan=2>4-MethylumbelliferylPhosphate</td></tr><tr><td rowspan=1 colspan=1>Detection</td><td rowspan=1 colspan=2>Chemiluminescence</td><td rowspan=1 colspan=2>Fluorescence</td></tr><tr><td rowspan=1 colspan=1>Calibration</td><td rowspan=1 colspan=2>Factory generated mastercurve with a single levelcalibration adjustmentevery 14 days.</td><td rowspan=1 colspan=2>Full calibration curve (sixstandards) with change inreagents.</td></tr><tr><td rowspan=1 colspan=1>Throughput</td><td rowspan=1 colspan=2>Single Sample</td><td rowspan=1 colspan=2>Batch</td></tr><tr><td rowspan=1 colspan=1>Time to Result</td><td rowspan=1 colspan=2>16 minutes</td><td rowspan=1 colspan=2>45 minutes to first result</td></tr><tr><td rowspan=1 colspan=1></td><td></td><td></td><td></td><td></td></tr></table>

<table><tr><td>Reagents Supplied as</td><td>Box of 50 disposable self contained reagent packs</td><td>Reagent Pack for 100 test</td></tr></table>

#

<table><tr><td colspan="6">Performance Characteristics:</td></tr><tr><td>Feature Precision</td><td colspan="3">FastPack® TSH Mean μlU/mL</td><td colspan="3">Abbott IMx® hTSH II</td></tr><tr><td rowspan="7"></td><td></td><td>%CV</td><td></td><td>Mean μIU/mL</td><td>%CV</td></tr><tr><td>Between Run 1</td><td></td><td></td><td>Run to Run</td><td></td></tr><tr><td>0.53 1.54</td><td>10.9 7.4</td><td>1 2</td><td>0.28 6.10</td><td>4.20</td></tr><tr><td>2 3 12.39</td><td>5.2</td><td></td><td></td><td>3.42</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Between Analyzer</td><td></td><td>Between Run</td><td>0.28 6.10</td><td>3.44 3.25</td></tr><tr><td>0.53 1.54 12.39</td><td>2.2 0.5 1.1</td><td>I 2</td><td></td><td></td></tr><tr><td></td><td>Between Reagent Lot 1 0.53 2 1.54</td><td>1.2 0.3</td><td></td><td></td><td></td></tr><tr><td>Analytical</td><td>3 12.39 0.01 μIU/mL</td><td>4.8</td><td></td><td>0.02 μIU/mL</td><td></td></tr><tr><td>Sensitivity Functional Sensitivity</td><td>0.13 μIU/mL</td><td></td><td></td><td>0.04 μIU/mL</td><td></td></tr><tr><td>Method Comparison</td><td>versus Abbott IMx Ultrasensitive hTSH II: n = 93</td><td></td><td></td><td></td><td>Range of values (IMx): 0.00 to 75.00 μIU/mL</td></tr><tr><td>Interfering Substances</td><td>y = 0.91 x + 1.26 r = 0.98</td><td></td><td></td><td>Range of values (FastPack): 0.03 to 64.25 μIU/mL</td><td></td></tr><tr><td>Bilirubin</td><td>No interference up to:</td><td></td><td></td><td>No interference up to:</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>n.d. = not detected</td><td>500 mIU/mL FSH 200,000 mlU/mL hCG</td><td>n.d. n.d. 200,000 mIU/mL hCG</td><td>1000 mIU/mL FSH</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>1000 mg/dL</td><td></td><td></td><td></td><td></td></tr><tr><td>Hemoglobin</td><td>40 mg/dL</td><td></td><td>10 mg/dL</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>1000 mg/dL</td><td></td><td></td></tr><tr><td>Triglycerides</td><td>1000 mg/dL</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>1200 mg/dl.</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Specificity</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>500 mIU/mL LH</td><td>n.d.</td><td></td><td>1000 mlU/mL LH</td><td>n.d.</td></tr></table>

# Qualigen, Incorporated

<table><tr><td rowspan=1 colspan=1>FunctionalSensitivity</td><td rowspan=1 colspan=2>0.13 μIU/mL</td><td rowspan=1 colspan=1>0.04 μlU/mL</td></tr><tr><td rowspan=1 colspan=1>MethodComparison</td><td rowspan=1 colspan=3>versus Abbott IMx Ultrasensitive hTSH II:n = 93Range of values (IMx): 0.00 to 75.00 μlU/mLRange of values (FastPack): 0.03 to 64.25 μIU/mLy = 0.91 x + 1.26r = 0.98</td></tr><tr><td rowspan=1 colspan=1>InterferingSubstancesBilirubinHemoglobinTriglycerides</td><td rowspan=1 colspan=1>No interference up to:40 mg/dL1000 mg/dL1000 mg/dL</td><td rowspan=1 colspan=2>No interference up to:10 mg/dL1000 mg/dL1200 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Specificityn.d. = not detected</td><td rowspan=1 colspan=1>500 mIU/mL LH    n.d.500 mIU/mL FSH  n.d.200,000 mIU/mL hCG n.d.</td><td rowspan=1 colspan=2>1000 mIU/mL LH    n.d.1000 mIU/mL FSH  n.d.200,000 mIU/mL hCG n.d</td></tr></table>

# JAN 4 2006

Ms. Dorothy Deinzer Peterson   
Vice President   
Quality Assurance and Regulatory Affairs   
Qualigen Incorporated   
2042 Corte del Nogal   
Carlsbad, CA 92011

Re: k052301 Trade/Device Name: FastPack $\textsuperscript { \textregistered }$ TSH Immunoassay FastPack $^ \mathrm { \textregistered }$ TSH Calibrator FastPack® TSH Controls Regulation Number: 21 CFR 862.1690 Regulation Name: Thyroid stimulating hormone test system Regulatory Class: Class II Product Code: JLW, JJX, JIT Dated: December 6, 2005 Received: December 14, 2005

Dear Ms. Peterson:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class II (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 -

This letter willallow you to begin marketing your device as described in your Section $5 1 0 ( \mathbf { k } )$ E premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

![](images/9b0d4894d92dfb78e0267f9b140e5215c3f58f457c7fe4c3b167f23bc6316f50.jpg)

Alberto Gutierez, Ph.D.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and Radiological Health

FastPack® TSH Immunoassay, FastPack® TSH Calibrator, FastPack® Controls

# Indications for Use

The FastPack® TSH Immunoassay is a paramagnetic particle, chemiluminescence immunoassay for the in vitro quantitative determination of Thyroid-Stimulating Hormone in human plasma. The measurements of thyroid stimulating hormone (TSH) produced by the anterior pituitary are used in the diagnosis of thyroid or pituitary disorders. The FastPack® TSH is designed for use with the FastPack® System.

The FastPack® TSH Calibrator is intended to calibrate the FastPack® System when used for the quantitative determination of TSH in human plasma.

The FastPack ® Controls are assayed quality control materials for the verification of the accuracy and precision of the FastPack® System when used for the quantitative determination of PSA in human serum and plasma, and TSH in human plasma.